Browsing Centre for Oral Immunobiology and Regenerative Medicine by Author "Baker, D"
Now showing items 1-7 of 7
-
Alemtuzumab depletion failure and neutralizing anti-drug antibodies: a case report and call for monitoring
Munger, K; Kang, A; Baker, D; Goodman, A; Samkoff, L (2020-12) -
Anti-drug antibodies to antibody-based therapeutics in multiple sclerosis.
Baker, D; Asardag, AN; Quinn, OA; Efimov, A; Kang, AS (2021-08-06)Multiple sclerosis is the major demyelinating autoimmune disease of the central nervous system. Relapsing MS can be treated by a number of approved monoclonal antibodies that currently target: CD20, CD25 (withdrawn), CD49d ... -
A cell-based assay for the detection of neutralizing antibodies against alemtuzumab.
Ali, L; Saxena, G; Jones, M; Leisegang, GR; Gammon, L; Gnanapavan, S; Giovannoni, G; Schmierer, K; Baker, D; Kang, AS (2020-02-25)Aim: The humanized anti-CD52 monoclonal antibody alemtuzumab depletes lymphocytes and is currently used to treat relapsing multiple sclerosis. During treatment, anti-alemtuzumab antibodies may develop and reduce effective ... -
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases
Baker, D; Roberts, CAK; Pryce, G; Kang, AS; Marta, M; Reyes, S; Schmierer, K; Giovannoni, G; Amor, S (2020-08-01) -
Immunogenicity of biologics used in the treatment of asthma.
Neunie, OAM; Rabbani, W; Baker, D; Chambers, ES; Pfeffer, PE; Kang, AS (2024-06-04)PURPOSE OF THE REVIEW: Asthma is a major global disease affecting adults and children, which can lead to hospitalization and death due to breathing difficulties. Although targeted monoclonal antibody therapies have ... -
Immunogenicity of biologics used in the treatment of inflammatory bowel disease: A review.
Bqain, M; Efimov, A; Baker, D; Kang, AS (2021-06-19)PURPOSE OF THE REVIEW: Here we critically evaluate the literature on immunotherapy failure in inflammatory bowel disease patients. In particular anti-drug antibody production, and subsequently loss of response as the primary ... -
Immunogenicity of biologics used in the treatment of moderate to severe psoriasis
Patel, V; Efimov, A; Baker, D; Kang, AS (IOS Press, 2021-06-11)The number of biologic drugs available for the treatment of psoriasis continue to expand. However, being biological proteins and thus potentially immunogenic, there is evidence that anti-drug-antibodies develop against the ...